| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -5.5 | -5.6 |
| EPS (diluted, $ a share) | $-0.06 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RNTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Rein Therapeutics, Inc.: key numbers
- Share price
- $0.4000Close, Nov 16
- Market cap
- $34.5M
- Shares outstanding
- 86.27MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Rein Therapeutics, Inc.
All →Rein Therapeutics Clinical Trial Data
Rein Therapeutics announced preliminary blinded Phase 2 data from its RENEW trial evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). The data showed that 33% of evaluable patients demonstrated improvement in forced vital capacity (FVC) at Week 12, with favorable safety and tolerability observed across the study population.
“As we continue to enroll patients in the study, today’s blinded look at the data shows encouraging lung function trends and a favorable safety and tolerability profile across the study population, reinforcing our confidence in the potential of LTI-03 to deliver a differentiated clinical and safety profile for patients with significant unmet need.”
Brian Windsor, Ph.D., President and Chief Executive Officer